Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.

Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.

Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress

Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress

LLTs Exposure Time and Major Vascular Risk Reduction

LLTs Exposure Time and Major Vascular Risk Reduction

Improving Lipid Management for Patients Post-ACS

Improving Lipid Management for Patients Post-ACS

Watch Prof. Pasquale Perrone-Filardi from Department of Clinical Medicine, Cardiovascular and Immunology Sciences, Federico II University, Naples sharing insights on improving lipid management for patients post-ACS.

Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines

Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines

The role of the patient in Achieving LDL-C Target

The role of the patient in Achieving LDL-C Target

Identifying and treating patients with high Lipidaemia risk post-ACS

Identifying and treating patients with high Lipidaemia risk post-ACS

Lipid management in patients with ACS/ASCVD

Lipid management in patients with ACS/ASCVD

In hospital outcomes in young patients with AMI: Results from Gulf Coast

In hospital outcomes in young patients with AMI: Results from Gulf Coast

Adherence and persistence analysis in patients treated with DAPT

Adherence and persistence analysis in patients treated with DAPT

Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)

Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)

Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?

Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?